INTRODUCTION {#sec0005}
============

Fewer than two-thirds of individuals with Parkinson's disease (PD) in the USA have seen a neurologist \[[@ref001]\]. Although study groups and multicenter research networks allow for the study of large numbers of PD patients at academic medical centers \[[@ref002]\], it is nonetheless estimated that only a small proportion of the PD population are represented in PD research. Thus, online tools that collect data from large numbers of PD patients, many of whom may not have access to research centers, could be of great value in self-reported patient-oriented research on PD.

While advances in technology, and availability and use of the internet and mobile devices make large online-only PD research cohorts feasible \[[@ref004]\], several factors are essential to consider regarding the utility of the data obtained on such "digital cohorts". First, determining the accuracy of patient-reported diagnosis is critical. Among non-neurologic populations, diagnostic accuracy of self-reported diabetes was high as confirmed by patients' primary care providers \[[@ref005]\]. Data on the accuracy of self-reported PD diagnosis are limited, and range from good agreement in a clinical trials population \[[@ref006]\] to poor agreement in a study comparing self-reported medical history and history in the electronic medical record \[[@ref007]\]. Second, the validity of unsupervised online-completion of scales that have been validated for in-person assessment should also be evaluated.

Data from the Patients Like Me (PLM) website provide an illustrative example in regard to these considerations. PLM is a for-profit website that collects data from a large number of individuals with self-reported medical conditions \[[@ref008]\]. While initially designed with the purpose of creating a network for amyotrophic lateral sclerosis patients, it has evolved into a research tool; PLM data have been shown to have utility in the validation and administration of online surveys for multiple sclerosis (MS) \[[@ref009]\] and may be useful to detect adverse events \[[@ref010]\]. However, among their group with self-identified MS, there were small but significant differences in several patient and disease characteristics compared to a clinic-based in-person evaluated cohort at a tertiary care center \[[@ref011]\]. The PLM group had younger age, greater education, were less likely to be male and white. They had a younger age at symptom onset, shorter disease duration, and were more likely to have relapsing-remitting disease. The PLM website also collects data from PD patients \[[@ref012]\]. Data from 6,074 patients with self-reported PD on the PLM website were compared to data from the Parkinson's Disease Data Organizing Center (PD-DOC) dataset which is a compilation of data from several clinical trials conducted in the USA from 2006--2011. The PLM group were younger than the PD-DOC group and reported increased symptom severity in the medication OFF state \[[@ref012]\]. While informative, the published PD PLM dataset is not specifically designed as a research study and collects data on only a subset of non-motor symptoms as assessed by only a few items on the Unified Parkinson's Disease Rating Scale \[[@ref013]\].

The Fox Insight (FI) study has recruited an online longitudinal cohort of individuals with self-reported PD, providing demographic and health-related information through the online platform foxinsight.org \[[@ref004]\]. One of its main goals is to obtain comprehensive longitudinal data on a large number of individuals with PD, and to act as a platform through which surveys can be administered to large numbers of PD patients. Understanding how the characteristics of the FI cohort compare to more traditionally-assessed cohorts would be useful towards determining some of the key factors discussed above. The primary objectives of this analysis were to provide a baseline description of the PD cohort in Fox Insight, and to compare self-reported demographic and medical history, disease characteristics, PD medication use, and motor and non-motor symptoms of the FI cohort to other recent observational research study cohorts assessed with in-person visits. This can inform future combined analyses of these populations. A secondary objective was to examine data completeness. Our hypothesis is that the FI cohort has similar characteristics and symptom prevalence as compared to demographically comparable individuals with PD assessed in-person, and that data completeness would be comparable to in-person assessments.

METHODS {#sec0010}
=======

Three comparison cohorts were selected based on accessibility of data and comparability of assessments. They were the Parkinson's Progression Markers Initiative (PPMI), Parkinson's Disease Biomarkers Project (PDBP), and the idiopathic PD (non-mutation carrier) arm of the cross-sectional LRRK2 consortium cohort (iPDLC). Only the PD subjects from these cohorts were examined. Where inclusion/exclusion criteria for a given cohort accounted for key differences in factors that influence PD expression (such as disease duration), analyses to stratify based on said differences were undertaken (see analysis section below).

Sample {#sec0015}
------

The minimum requirements for inclusion of subjects in this analysis were available data on subject age, gender, and year of PD diagnosis. Additional criteria for inclusion of data from subjects from each cohort are specified below.

### Fox Insight {#sec0020}

Details of the Fox Insight Study are available online \[[@ref004]\]. Briefly, any individual aged 18 or older, with or without PD, who is able to provide online informed consent, is eligible to enroll in FI. Recruitment occurs through a variety of approaches including in-person referral (at educational/research events and clinician referrals) and online strategies (ads on social network platforms, email invitations, electronic newsletters) \[[@ref014]\]. Within the Fox Insight database, subjects were included for this analysis if they met the following criteria: had (i) participated in Fox Insight starting March 7, 2017 (the date on which new questionnaires and platform updates were launched), (ii) self-reported a diagnosis of PD, and (iii) completed a baseline visit as of February 19, 2019. A completed baseline visit was defined as completion of questions on age at survey, gender, year of PD diagnosis, and completion of \> 80% of items on the Movement Disorders Society-Unified Parkinson's Disease Rating scale (MDS-UPDRS) II or Non-Motor Symptom Questionnaire (NMS-QUEST). Eight participants whose diagnosis date was listed as the same as their date of birth and 2,271 participants with an incomplete baseline visit were excluded from analysis. Similar data inclusion/exclusion criteria were applied across all cohorts, to ensure a minimum amount of data were available on all included subjects. The final sample for the Fox Insight PD cohort was *n* = 12,654.

### PPMI cohort {#sec0025}

Details regarding the PPMI study have been published \[[@ref015]\] and are available at ppmi-info.org. Briefly, PPMI recruited 423 individuals with PD diagnosed within 2 years of enrollment, not on dopaminergic therapy, Hoehn and Yahr ≤2, and with abnormal dopamine transporter (DAT) SPECT scan. PPMI data used in this analysis were downloaded on November 9, 2018. Individuals in PPMI who completed less than 80% of items on the MDS-UPDRS II at baseline were excluded (*n* = 1). The final sample for the PPMI cohort was *n* = 422.

### iPDLC cohort {#sec0030}

The cross-sectional LRRK2 consortium cohort consists of PD participants with or without a LRRK2 mutation recruited from family, community or clinic-based studies that were being conducted at consortium-participating centers \[[@ref017]\]. In family-based studies individuals were invited to participate based on a family history of PD. For this analysis, only subjects in the non-mutation arm (idiopathic PD LRRK2 Consortium subjects, iPDLC), recruited from consortium centers in 7 countries (USA, Israel, Tunisia, Germany, Spain, Norway, and Canada), were included in this analysis. Participants in 8 research studies contributed to this analysis: five studies were family-based, and three were clinic-based. There were no restrictions on age or disease duration for inclusion in the LRRK2 cohort consortium. Data used in this analysis were downloaded on September 12, 2016. Seventeen individuals were excluded from the analysis as they did not complete \> 80% of items on the UPDRS II at baseline. The final sample for the iPDLC cohort was *n* = 508.

### PDBP cohort {#sec0035}

The National Institute of Neurological Disorders and Stroke (NINDS) PDBP cohort included in this analysis is comprised of PD participants recruited at 10 academic centers in the United States across 11 research projects ([Supplementary Table 1](#S1){ref-type="supplementary-material"}). All projects are observational studies that share 2 inclusion criteria for their PD cohorts: diagnosis of PD based on UK PD Society Brain Bank criteria, and the ability to provide written informed consent or have an informed consent proxy. Otherwise, each project has its own inclusion/exclusion criteria, including age, PD disease duration, and PD severity \[[@ref018]\]. For this analysis, all subjects who had PD listed as their primary diagnosis on the PDBP Neurological Examination form and who had completed a study visit at the time of PDBP data download (April 1, 2019) were included in this analysis. No individuals were excluded as all participants completed \> 80% of items on the MDS-UPDRS II at baseline. The final sample for the PDBP cohort was *n* = 700.

This study was performed in accordance with the Declaration of Helsinki. The Fox Insight study is approved by the New England Institutional Review Board, and online consent is obtained from each participant at enrollment.

Assessments {#sec0040}
-----------

Data from baseline visits for participants in each cohort were compared. For the PPMI, PDBP and iPDLC groups, these visits consisted of assessments gathered on a single day during an in-person visit. At the time of data download, the baseline visit for the FI cohort could be completed over a 3-month period. However, the vast majority of participants completed all assessments over a single day ([Supplementary Table 2](#S1){ref-type="supplementary-material"}).

The FI study administers questions on demographics, non-motor symptoms, quality of life, activities of daily living function, medical history, and medications. Study assessments administered in the comparator cohorts are detailed in [Supplementary Tables 3--5](#S1){ref-type="supplementary-material"}. In instances where identical standardized questionnaires were administered in FI and any given comparator cohort, responses to each question were compared directly. Otherwise, expert opinion (of the authors) was used to determine responses on different questionnaires that reflect presence/absence of a given symptom and the prevalence of the symptom was then compared across cohorts. A brief description follows, and details are provided in [Supplementary Tables 3--5](#S1){ref-type="supplementary-material"}.

### Demographics {#sec0045}

Age at survey, disease duration, race, ethnicity, and education were compared.

### MDS-UPDRS II \[[@ref020]\] {#sec0050}

This assesses motor aspects of experiences of daily living. Responses were dichotomized into 0 vs \> 0 and compared across cohorts that collected this scale (FI, PDBP, PPMI).

### Comorbid vascular risk factors {#sec0055}

Only the FI cohort collects medical conditions as categorical variables. The other cohorts either do not collect medical history (iPDLC, PDBP) or collect it as free-text (PPMI). Therefore, for practicality, it was determined that only a brief list of medical conditions could be compared across any of the cohorts for this analysis, and vascular risk factors were selected given their putative relevance to several key outcomes in PD (e.g., motor impairment, cognitive decline). FI collects data on vascular risk factors by asking participants for the presence/absence of each. As for the PPMI cohort, during the PPMI screening visit, all medical conditions reported by the patient are recorded in the medical conditions log. Self-reported vascular risk factors were ascertained from the log.

### Health-related quality of life (QOL) {#sec0060}

Parkinson's Disease Quesitonnaire-8 (PDQ) scores from FI were compared to a score derived from the Parkinson's Disease Questionnaire-39 administered in PDBP. Responses by the PDBP cohort on the items on the PDQ39 that are also present on the PDQ8 (questions 7, 12, 17, 25, 27, 31, 35, 37) were used to derive a PDQ8 score as described \[[@ref021]\]. No other comparator cohort had a quality of life assessment at the time of data download.

### Non-motor symptoms {#sec0065}

Fox Insight assesses non-motor symptoms via the NMS-QUEST \[[@ref022]\]. Responses on these items were compared to responses on questions collected in other cohorts that query similar domains. These include, in PPMI, the MDS-UPDRS part I, Geriatric Depression Scale---15 item (GDS-15) \[[@ref024]\], the REM sleep behavior Disorder Questionnaire (RBDSQ) \[[@ref025]\], single question for RBD (RBDQ1), Epworth sleepiness scale (ESS) \[[@ref026]\], Scales for Outcomes in Parkinson's-Autonomic (SCOPA-AUT) \[[@ref027]\], in PDBP the MDS-UPDRS part 1, and in the iPDLC the UPDRS, Mayo sleep questionnaire \[[@ref028]\], GDS-15, ESS, and the SCOPA-AUT.

### PD medications ([Supplementary Table 5](#S1){ref-type="supplementary-material"}) {#sec0070}

Fox Insight asks participants to select any medication they are prescribed from a list of generic and trade name PD medications. PPMI collects data on use of levodopa, agonist, or "other" PD medication. Responses on that case report form (CRF) were used to compare to use of dopaminergic medication in FI. In PPMI, medication use is also collected on a free-text medication log.

### Use of supplements {#sec0075}

FI participants are asked if they are taking any of the following supplements or vitamins (more than one can be selected): coenzyme Q10, vitamin E, vitamin C, vitamin D, creatine. Use of vitamins E, C and D was extracted from the PPMI medication log.

Analysis {#sec0080}
--------

The FI cohort was compared to each of the 3 comparator cohorts separately (comparator cohorts were not compared to each other). For continuous variables, the mean, standard deviation, as well as minimum and maximum values are provided. For categorical variables, the percentage of participants who provided positive endorsements out of the total number of participants who provided a response are shown (i.e., not answered (NA) or prefer not to answer (PNA) responses were excluded from the denominator). In [Supplementary Tables 6--10](#S1){ref-type="supplementary-material"}, information regarding the percentage of NA or PNA responses (out of the total size of the cohort) is provided for each variable.

Univariate comparisons were performed across all measures. For categorical measures, chi-square tests were performed and Cramer's V effect sizes for significant *post-hoc* comparisons between FI and the other cohorts (small: 0.1, medium: 0.3, and large: 0.5) are reported. For continuous measures, one-way ANOVAs were performed and Cohen's d effect sizes for significant *post-hoc* comparisons between FI and the other cohorts (small: 0.2, medium: 0.5, and large: 0.8) are reported. A Bonferroni adjusted alpha level of 0.000095 was used to account for the multiple comparisons being performed.

In order to account for differences in disease duration between the FI and PPMI cohort (resulting from the inclusion criteria of the PPMI cohort as stated above), only the subgroup of FI participants with ≤2 years disease duration, from here on referred to as the "early FI cohort", were compared to the PPMI cohort.

RESULTS {#sec0085}
=======

The final sample for each cohort was FI *n* = 12,654 (early FI = 4,072), PPMI *n* = 422, PDBP *n* = 700, iPDLC *n* = 508.

Among the FI cohort, the physician who diagnosed PD (as reported by the participant) was a general neurologist in 5264 (41.6%) cases, a neurologist specializing in movement disorders in 5338 (42.18%), and a primary care physician in 562 (4.44%). Multiple sources of diagnosis was selected in 1307 (10.33%) cases.

Demographic and disease characteristics {#sec0090}
---------------------------------------

Demographic characteristics of each cohort are shown in [Table 1](#jpd-10-jpd191808-t001){ref-type="table"}. The FI, PDBP, and iPDLC cohort had similar mean ages of 65-66 years. The PPMI cohort was significantly younger than the early FI cohort (64.31 vs 61.62 years). The proportion of females was significantly higher in FI (45.56%) compared to PDBP (35.71%) and in early FI (46.93%) compared to PPMI (34.36%). The proportion of non-whites was low across all cohorts though significantly greater in PPMI (7.58%) compared to early FI (2.89%) and in FI (3.15%) compared to iPDLC (0). The FI cohort had significantly greater educational attainment as compared to all other cohorts. As for PD disease duration, it was comparable in FI (5.21 years) and iPDLC (4.69 years), and longer in PDBP (6.42 years) compared to FI. History of PD in a 1st degree relative was significantly more often reported in early FI compared to PPMI (22.28% vs 13.06%).

###### 

Baseline demographic characteristics of the Fox Insight cohort and comparator cohorts. Percentages are based on number endorsing divided by specified sample in parenthesis. Blank cells indicate data were not collected in a given cohort

  Item                               Fox Insight        Early Fox Insight          PPMI               PDBP              iPDLC         Sig. diff  *Post-hoc* effect sizes
  ----------------------------- ---------------------- -------------------- ------------------ ------------------ ------------------ ----------- --------------------------
  Age (mean (SD))                    65.77 (9.49)           64.31 (10)         61.62 (9.68)       65.2 (9.09)       66.67 (10.62)        \*      Early FI vs. PPMI: 0.27
  Range (years)                      (18.1--98.8)          (25.2--93.4)       (33.5--84.88)      (34.75--87.5)         (26--89)                  
  Sex                                                                                                                                    \*      FI vs. PDBP: 0.043
    Male                         54.44% (6889/12654)    53.07% (2161/4072)   65.64% (277/422)   64.29% (450/700)   60.43% (307/508)              Early FI vs. PPMI: 0.072
    Female                       45.56% (5765/12654)    46.93% (1911/4072)   34.36% (145/422)   35.71% (250/700)   39.57% (201/508)              
  BMI (kg/m^2^)                      26.79 (6.54)          27.21 (5.95)        27.15 (4.63)                                                      
  Range                             (8.87--231.93)        (8.87--165.31)      (16.66--43.76)                                                     
  Race                                                                                                                                   \*      FI vs. iPDLC: 0.034
    White                        96.85% (12183/12579)   97.11% (3933/4050)   92.42% (390/422)   96.85% (677/699)    100% (508/508)               Early FI vs. PPMI: 0.075
    NonWhite                      3.15% (396/12579)      2.89% (117/4050)     7.58% (32/422)     3.15% (22/699)       0% (0/508)                 
  Ethnicity                                                                                                                                      
    Hispanic                      3.81% (469/12317)      3.28% (131/3997)     2.13% (9/422)      1.92% (13/678)      2.5% (1/40)                 
    NonHispanic                  96.19% (11848/12317)   96.72% (3866/3997)   97.87% (413/422)   98.08% (665/678)    97.5% (39/40)                
  Education                                                                                                                              \*      FI vs. iPDLC: 0.102
    Less than 9 years             0.98% (123/12606)      0.86% (35/4054)      1.66% (7/422)      0.29% (2/700)      2.82% (14/497)               FI vs. PDBP: 0.053
    9--12 years                   8.83% (1113/12606)     8.53% (346/4054)    16.11% (68/422)    15.71% (110/700)   19.92% (99/497)               Early FI vs. PPMI: 0.078
    13--16 years                 55.39% (6982/12606)    56.83% (2304/4054)   49.76% (210/422)   52.86% (370/700)   32.39% (161/497)              
    More than 16 years           34.81% (4388/12606)    33.77% (1369/4054)   32.46% (137/422)   31.14% (218/700)   44.87% (223/497)              
  PD Duration (mean years)           5.21 (5.21)            0.94 (0.6)         0.55 (0.54)        6.42 (5.48)        4.69 (4.91)         \*      FI vs. PDBP: 0.232
  Range                               (0--62.5)               (0--2)           (0.03--2.99)        (0--38.33)          (0--35)                   Early FI vs. PPMI: 0.656
    0--2 years                   30.73% (3888/12654)    95.50% (3888/4072)   96.68% (408/422)   23.29% (163/700)   31.89% (162/508)      \*      FI vs. PDBP: 0.035
    2--5 years                   30.29% (3833/12654)     4.52% (184/4072)     3.32% (14/422)    25.43% (178/700)   27.95% (142/508)              
    5--10 years                  24.02% (3039/12654)                                             29% (203/700)     25.79% (131/508)              
    10+ years                    14.97% (1894/12654)                                            22.29% (156/700)   14.37% (73/508)       \*      FI vs. PDBP: 0.044
  Family History (1st Degree)    22.32% (2371/10621)    22.28% (722/3241)    13.06% (55/421)    17.82% (103/578)   16.67% (81/486)       \*      Early FI vs. PPMI: 0.07

Self-reported vascular risk factors {#sec0095}
-----------------------------------

Self-reported vascular risk factors are shown in [Table 2](#jpd-10-jpd191808-t002){ref-type="table"}. The proportion reporting hypertension was higher in the early FI cohort compared to PPMI cohort (43.3% and 27.49%, respectively). The same was true for high cholesterol (47.28% in early FI, 21.8% in PPMI). The prevalence of coronary artery disease was comparable. Diabetes was twice as often reported in the early FI cohort as compared to PPMI cohort, and stroke was nearly 5 times more often reported, though these differences did not reach statistical significance.

###### 

Vascular risk factors present in FI^1^ and PPMI. Percentages are based on number endorsing divided by specified sample in parenthesis

  Item                                  Fox Insight       Early Fox Insight         PPMI         Sig. diff   *Post-hoc* effect sizes
  -------------------------------- --------------------- ------------------- ------------------ ----------- -------------------------
  Hypertension                      40.89% (5157/12613)   43.3% (1758/4060)   27.49% (116/422)      \*       Early FI vs PPMI: 0.092
  High Cholesterol^1^                45.08% (962/2134)    47.28% (252/533)     21.8% (92/422)       \*       Early FI vs PPMI: 0.262
  Coronary Artery Disease            5.95% (625/10498)     5.6% (198/3534)     5.21% (22/422)               
  Peripheral Arterial Disease^1^      2.2% (47/2134)       2.63% (14/533)        0% (0/422)                 
  Atrial Fibrillation                4.84% (508/10498)     4.5% (159/3534)     2.13% (9/422)                
  Stroke or TIA                       5% (630/12602)      4.98% (202/4056)     0.47% (2/422)                
  Diabetes                          9.25% (1167/12618)    10.71% (435/4063)    5.21% (22/422)               

^1^Note, only a subset of Fox Insight participants received questions regarding high cholesterol and peripheral arterial disease.

Motor experiences of daily living {#sec0100}
---------------------------------

Regarding motor experiences of daily living, the proportion reporting \> 0 on each item of the MDS-UPDRS II are shown in [Table 3](#jpd-10-jpd191808-t003){ref-type="table"} and depicted in [Fig. 1](#jpd-10-jpd191808-g001){ref-type="fig"}. There were no significant differences in the FI and PDBP cohort on any item. Certain motor symptoms were more frequent in the early FI cohort when compared to the PPMI cohort, specifically difficulty turning in bed (47.22% vs 25.59%), getting out of bed/car/chair (61.71% vs 38.63%), walking and balance (59.45%, 36.73%), and freezing of gait (19.28% vs 4.74%). Falling was reported by similar proportions of the FI and PDBP cohort (20.25% vs 23.27% respectively).

###### 

Motor experiences of daily living as assessed with the MDS-UPDRS II. MDS-UPDRS II = Movement Disorders Society Unified Parkinson's Disease Rating Scale part II

  Item                              Fox Insight         Early Fox Insight           PPMI                  PDBP           Sig. diff  *Post-hoc* effect sizes
  ---------------------------- ---------------------- --------------------- -------------------- ---------------------- ----------- --------------------------
  MDS-UPDRS II Total            12.11 (8.26) (0--52)   9.15 (6.76) (0--46)   5.9 (4.19) (0--22)   11.59 (8.43) (0--46)      \*      Early FI vs. PPMI: 0.496
  2.1 Speech                    58.48% (7400/12654)    46.88% (1909/4072)     33.89% (143/422)      55.86% (391/700)        \*      Early FI vs. PPMI: 0.075
  2.2 Saliva and Drooling       51.36% (6499/12654)    42.98% (1750/4072)     36.49% (154/422)      49.43% (346/700)                
  2.3 Chewing and Swallowing    35.43% (4483/12654)    26.94% (1097/4072)     13.03% (55/422)       31.43% (220/700)        \*      Early FI vs. PPMI: 0.092
  2.4 Eating Tasks              48.01% (6075/12654)      39% (1588/4072)      28.2% (119/422)       44.86% (314/700)        \*      Early FI vs. PPMI: 0.063
  2.5 Dressing                  60.76% (7689/12654)     48.5% (1975/4072)     40.52% (171/422)      58.29% (408/700)                
  2.6 Hygiene                   43.24% (5471/12654)    32.93% (1341/4072)     25.59% (108/422)       38% (266/700)                  
  2.7 Handwriting               70.82% (8961/12654)    61.47% (2503/4072)     61.85% (261/422)       68% (476/700)                  
  2.8 Doing Hobbies and         62.93% (7963/12654)    50.98% (2076/4072)     36.73% (155/422)      58.43% (409/700)        \*      Early FI vs. PPMI: 0.082
  Other Activities                                                                                                                  
  2.9 Turning in Bed            62.67% (7930/12654)    47.22% (1923/4072)     25.59% (108/422)      55.65% (389/699)        \*      Early FI vs. PPMI: 0.126
  2.10 Tremor                   79.71% (10086/12654)   81.34% (3312/4072)     86.02% (363/422)      78.57% (550/700)                
  2.11 Getting Out of Bed,      71.13% (9001/12654)    61.71% (2513/4072)     38.63% (163/422)      67.71% (474/700)        \*      Early FI vs. PPMI: 0.136
  a Car, or a Deep Chair                                                                                                            
  2.12 Walking and Balance      69.57% (8804/12654)    59.45% (2421/4072)     36.73% (155/422)      64.09% (448/699)        \*      Early FI vs. PPMI: 0.133
  2.13 Freezing                 31.28% (3958/12654)     19.28% (785/4072)      4.74% (20/422)       32.71% (229/700)        \*      Early FI vs. PPMI: 0.11

![Heat map depicting percentage of participants in the FI cohort compared to the PPMI, PDBP, and iPDLC cohorts with (A) score of \> 0 on MDS-UPDRS II items and (B) non-motor symptoms. (C) Comparison in score of \> 0 on MDS-UPDRS II items between the early FI cohort and PPMI. (D) Comparison of non-motor symptoms in early FI cohort compared to PPMI cohort. Grey cells indicate not collected. FI, Fox Insight; iPDLC, idiopathic PD LRRK2 Consortium subjects; MDS-UPRDS, Movement Disorders Unified Parkinson's Disease Rating Scale; PD PDBP, Parkinson's Disease Biomarker Program; PPMI, Parkinson's Progression Markers Initiative.](jpd-10-jpd191808-g001){#jpd-10-jpd191808-g001}

Health-related quality of life {#sec0105}
------------------------------

Comparing PDQ8 scores from FI to the derived PDQ score from the PDQ39 administered in PDBP, scores were higher (worse) in FI compared to PDBP.

Non-motor symptoms {#sec0110}
------------------

Several non-motor symptoms tended to be reported by a higher proportion of FI participants, though the magnitude of differences were small for most ([Table 4](#jpd-10-jpd191808-t004){ref-type="table"}, [Fig. 1](#jpd-10-jpd191808-g001){ref-type="fig"}). Differences in possible RBD among cohorts varied according to what measure/definition was used. Possible RBD was significantly more prevalent in the early FI cohort (indicated by a positive response to the RBDQ1) compared to the PPMI cohort (indicated by a score on the RBDSQ \> 5), 35.53% vs 25.78% respectively. On the other hand, when items on the NMS-QUEST in the early FI cohort were compared to individual items on the RBDSQ in PPMI, a smaller proportion of FI participants reported vivid dreams than in PPMI (31.25% vs 59%), while a similar proportion of participants reported talking / moving in sleep (27.31% vs 32.07%). The iPDLC cohort reported significantly fewer vivid dreams (6.92% vs 33.93%) and talking/moving in sleep (5.53% vs 32.71%) compared to the FI cohort.

###### 

Quality of life and non-motor symptoms

  Item                                         Fox Insight            Early Fox Insight             PPMI                  PDBP                 iPDLC         Sig. diff  *Post-hoc* effect sizes
  -------------------------------------- ------------------------ -------------------------- ------------------ ------------------------ ------------------ ----------- --------------------------
  PDQ8 Total Score                        21.38 (16.79) (0--100)   17.36 (15.45) (0--93.75)                      16.6 (13.7) (0--65.62)                         \*      FI vs. PDBP: 0.287
  Acting out dreams                        41.54% (5052/12163)        35.53% (1411/3971)      25.78% (108/419)      48.01% (325/677)       35.85% (19/53)       \*      FI vs. PPMI: 0.057
                                                                                                                                                                        Early FI vs. PPMI: 0.058
  Dribbling of saliva                      27.53% (3419/12421)        21.21% (851/4013)       38.76% (138/356)                            43.16% (82/190)       \*      FI vs. iPDLC: 0.042
                                                                                                                                                                        Early FI vs. PPMI: 0.114
  Olfactory change/loss                    32.65% (4055/12421)        28.71% (1152/4013)                                                                                
  Difficulty swallowing/choking            28.26% (3510/12421)        22.48% (902/4013)       13.03% (55/422)                             21.26% (108/508)      \*      Early FI vs. PPMI: 0.066
  Nausea/Vomiting                           21.1% (2621/12421)        22.65% (909/4013)                                                                                 
  Constipation                             53.84% (6688/12421)        46.15% (1852/4013)      54.5% (230/422)                             67.19% (129/192)              
  Fecal Incontinence                       12.26% (1523/12421)        10.84% (435/4013)                                                                                 
  Incomplete Bowel Emptying                43.73% (5432/12421)        39.57% (1588/4013)                                                                                
  Urgency to pass urine                    67.16% (8342/12421)        61.08% (2451/4013)      27.49% (116/422)                            23.56% (45/191)       \*      FI vs. iPDLC: 0.112
                                                                                                                                                                        Early FI vs. PPMI: 0.199
  Unexplained pain                         36.28% (4506/12421)        34.81% (1397/4013)                                                                                
  Change in weight                         11.56% (1436/12421)        10.57% (424/4013)                                                                                 
  Memory difficulties                      48.06% (5969/12421)        45.5% (1826/4013)       25.36% (107/422)      45.64% (319/699)      46.85% (238/508)      \*      Early FI vs. PPMI: 0.118
  Loss of interest                         35.26% (4380/12421)        34.14% (1370/4013)      16.82% (71/422)       25.32% (177/699)      37.7% (190/504)       \*      FI vs. PDBP: 0.046
                                                                                                                                                                        Early FI vs. PPMI: 0.107
  Hallucinations                           11.08% (1376/12421)         7.48% (300/4013)        3.08% (13/422)       10.59% (74/699)       29.53% (150/508)      \*      FI vs. iPDLC: 0.111
  Difficulty concentrating or focusing     46.54% (5781/12421)        43.43% (1743/4013)                                                                                
  Feeling sad, low or blue                  50.9% (6322/12421)        52.28% (2098/4013)      23.7% (100/422)       30.19% (211/699)      33.6% (170/506)       \*      FI vs. iPDLC: 0.067
                                                                                                                                                                        FI vs. PDBP: 0.093
                                                                                                                                                                        Early FI vs. PPMI: 0.167
  Anxiety/panic                            36.91% (4584/12421)        37.2% (1493/4013)       35.78% (151/422)      42.63% (298/699)                                    
  Change in libido                         35.74% (4439/12421)        35.14% (1410/4013)                                                                                
  Sexual dysfunction                       33.37% (4145/12421)        28.71% (1152/4013)      48.33% (202/418)                            55.93% (99/177)       \*      FI vs. iPDLC: 0.055
                                                                                                                                                                        Early FI vs. PPMI: 0.124
  Light headed/Dizzy                       44.26% (5498/12421)        43.58% (1749/4013)      32.3% (115/356)                             42.33% (80/189)       \*      Early FI vs. PPMI: 0.061
  Falling                                  20.25% (2515/12421)        14.25% (572/4013)                                                   23.27% (114/490)              
  Daytime sleepiness                       22.59% (2806/12421)        17.94% (720/4013)        9.03% (38/421)                               8.89% (4/45)        \*      Early FI vs. PPMI: 0.068
  Vivid/Frightening dreams                 33.93% (4214/12421)        31.25% (1254/4013)       59% (249/422)                               6.92% (35/506)       \*      FI vs. iPDLC: 0.111
                                                                                                                                                                        Early FI vs. PPMI: 0.171
  Talking/Moving in sleep                  32.71% (4063/12421)        27.31% (1096/4013)      32.07% (135/421)                             5.53% (28/506)       \*      FI vs. iPDLC: 0.113
  Unpleasant sensations in legs            47.16% (5858/12421)        42.74% (1715/4013)                                                                                
  Swelling of legs                         19.39% (2409/12421)        15.47% (621/4013)                                                                                 
  Excessive sweating                       24.54% (3048/12421)        20.68% (830/4013)                                                                                 
  Double vision                             17.3% (2149/12421)        13.16% (528/4013)                                                                                 
  Delusions                                 3.53% (439/12421)          2.27% (91/4013)         3.08% (13/422)       10.59% (74/699)                             \*      FI vs. PDBP: 0.081

PD medications ([Table 5](#jpd-10-jpd191808-t005){ref-type="table"}) {#sec0115}
--------------------------------------------------------------------

Use of levodopa was comparable in the FI (77.55%) and PDBP cohort (78.64%). Dopamine agonist use was significantly more common in the PDBP (49.07%) cohort compared to FI (32.08%), as was use of other PD medications (64.71% vs 33.71% respectively). All PD medications were significantly more commonly reported in early FI compared to PPMI, as expected based on PPMI inclusion criteria.

###### 

Dopaminergic medications and supplement use. NA = not answered (missing)

  Item                                  Fox Insight            PPMI               PDBP         Sig. diff  *Post-hoc* effect sizes
  -------------------------------- --------------------- ----------------- ------------------ ----------- -------------------------
  Levodopa                          77.55% (9792/12626)     0% (0/422)      78.64% (508/646)              
  Dopamine agonist                  32.08% (4051/12626)     0% (0/422)      49.07% (317/646)      \*      FI vs. PDBP: 0.077
  Other PD med                      33.71% (4256/12626)     0% (0/422)      64.71% (418/646)      \*      FI vs. PDBP: 0.139
  Vitamin                           66.67% (8415/12622)   16.82% (71/422)   38.54% (249/646)      \*      FI vs. PDBP: 0.127
  Qoenzyme q10                       19% (2398/12622)     15.17% (64/422)    6.81% (44/646)       \*      FI vs. PDBP: 0.067
  Stratified by disease duration                                                                          
  Levodopa                                                                                                
    0--2 years                      59.71% (2316/3879)      0% (0/408)      56.03% (79/141)       \*      FI vs. PPMI: 0.351
    2--5 years                      77.72% (2969/3820)       0% (0/14)       75% (123/164)        \*      FI vs. PPMI: 0.11
    5--10 years                     90.15% (2737/3036)                      82.89% (155/187)              
    10+ years                        93.6% (1770/1891)                      98.05% (151/154)              
  Dopamine agonist                                                                                        
    0--2 years                       20.01% (776/3879)      0% (0/408)      29.79% (42/141)       \*      FI vs. PPMI: 0.151
    2--5 years                      30.21% (1154/3820)       0% (0/14)       43.9% (72/164)               
    5--10 years                     42.36% (1286/3036)                      60.96% (114/187)      \*      FI vs. PDBP: 0.084
    10+ years                        44.16% (835/1891)                      57.79% (89/154)               
  Other PD med                                                                                            
    0--2 years                       20.98% (814/3879)      0% (0/408)      46.81% (66/141)       \*      FI vs. PPMI: 0.155
                                                                                                          FI vs. PDBP: 0.112
    2--5 years                       34.4% (1314/3820)       0% (0/14)      58.54% (96/164)       \*      FI vs. PDBP: 0.097
    5--10 years                     42.69% (1296/3036)                      74.33% (139/187)      \*      FI vs. PDBP: 0.146
    10+ years                         44% (832/1891)                        75.97% (117/154)      \*      FI vs. PDBP: 0.166
  Vitamin                                                                                                 
    0--2 years                      67.83% (2633/3882)    16.91% (69/408)   37.59% (53/141)       \*      FI vs. PPMI: 0.308
                                                                                                          FI vs. PDBP: 0.116
    2--5 years                      66.45% (2541/3824)     14.29% (2/14)    42.68% (70/164)       \*      FI vs. PDBP: 0.096
    5--10 years                     66.94% (2031/3034)                      41.71% (78/187)       \*      FI vs. PDBP: 0.121
    10+ years                       64.29% (1210/1882)                      31.17% (48/154)       \*      FI vs. PDBP: 0.177
  Coenzyme q10                                                                                            
    0--2 years                       20.94% (813/3882)    14.22% (58/408)    6.38% (9/141)        \*      FI vs. PDBP: 0.062
    2--5 years                       19.87% (760/3824)     42.86% (6/14)     9.15% (15/164)               
    5--10 years                      17.24% (523/3034)                       6.95% (13/187)               
    10+ years                        16.05% (302/1882)                       4.55% (7/154)                

Missing data {#sec0120}
------------

Inclusion criteria for this analysis required \> 80% completion of the MDS-UPDRS II in FI, PDBP, and PPMI, and \> 80% completion of UPDRS II in iPDLC; numbers excluded due to incomplete MDS-UPDRS or UPDRDS are described in the "Sample" section above. Otherwise, while for the most part missing data were not noted to be common in the FI cohort as compared to other cohorts ([Supplementary Tables 6--10](#S1){ref-type="supplementary-material"}, [Fig. 1](#jpd-10-jpd191808-g001){ref-type="fig"}), family history was significantly more likely to be missing in early FI (20.41%) compared to PPMI (0.24%) and in FI (16.07%) compared to iPDLC (4.33%) ([Supplementary Table 6](#S1){ref-type="supplementary-material"}). Due to changes in the FI medical history questionnaire and schedule of activities (see Assessments section above), data on several vascular risk factors were missing from the early FI cohort ([Supplementary Table 7](#S1){ref-type="supplementary-material"}). On the other hand, ethnicity data were more frequently missing in PDBP and iPDLC as compared to FI. The iPDLC cohort had significantly more missing data on education compared to FI ([Supplementary Table 6](#S1){ref-type="supplementary-material"}). Comparisons in prevalence of non-motor symptoms between the FI cohort and iPDLC cohort were limited due to substantial missing data in the iPDLC cohort, especially for the items daytime sleepiness, drooling, possible RBD, constipation, urinary urgency, and difficulty having sex ([Supplementary Tables 8-9](#S1){ref-type="supplementary-material"}).

DISCUSSION {#sec0125}
==========

In this analysis, we compare the Fox Insight cohort, a large online-only self-reported PD sample, to observational research cohorts assessed with in-person visits. In general, we found that the FI cohort is comparable to the other cohorts. Some differences exist, albeit small for the most part, which likely represent a combination of differences in inclusion/exclusion criteria for the in-person cohorts, differences in assessments, and the recruitment and data collection method. We consider our results in relation to potential threats to the quality of online-only studies: patient characteristics, self-reported medical conditions and medications, symptoms profile, missing data, and values out of expected range.

Patient characteristics {#sec0130}
-----------------------

PD research studies are lacking in gender, ethnic, and racial diversity, with a significant over-representation of males and whites, even when accounting for the known demographic distribution of PD \[[@ref029]\]. Females are disproportionately under-represented in PD research \[[@ref031]\]. One putative advantage of online cohorts is allowing patients who may not otherwise enroll in research, due to geographic reasons, transportation limitations, or other reasons, to participate. The FI cohort did have substantially more females with PD participating as compared to other cohorts, suggesting that the FI cohort has the potential to reduce barriers to research participation. However, ethnic and racial diversity remains limited. Recruitment strategies aimed at increasing diversity in FI are underway \[[@ref014]\].

Self-reported medical conditions and medications {#sec0135}
------------------------------------------------

Self-reported medical history, and especially cardiovascular history, is particularly prone to inaccurate reporting \[[@ref032]\]. This is important to consider when interpreting the higher prevalence of vascular risk factors in the FI cohort compared to the PPMI cohort. Future work to validate and improve upon this in FI is also needed. On the other hand, it is possible that the FI cohort allows for participation of individuals with medical comorbidities that might otherwise be excluded from other, in-person observational studies. While self-reported use of medications is accurate for other chronic diseases \[[@ref033]\], there are few data on the accuracy of self-reported PD medications as ascertained by survey. Given that, particular attention is needed in interpreting FI data on self-reported medications. It is reassuring that levodopa use was similar in FI and PDBP, but significantly greater use of dopamine agonists and other PD medications could indicate either differences in prescribing trends, or rather an under-reporting of use of non-levodopa agents in FI.

Symptoms reported by the study population {#sec0140}
-----------------------------------------

In terms of non-motor symptoms, the FI cohort demonstrates a high prevalence of many non-motor symptoms including constipation, urinary urgency, sexual dysfunction, memory problems, light-headedness, and depressive symptoms. The higher prevalence of some motor and non-motor symptoms we saw in the FI cohort compared to the other cohorts may be indicative of the ability of an online platform to include a more severe phenotype and representative sample than is able to participate in in-person studies. Regarding the substantial differences in possible RBD/dream related phenomena, while we cannot rule out true cohort differences, the findings more likely reflect differences in the assessments used as well as the challenges of measuring RBD in PD \[[@ref035]\].

Missing data {#sec0145}
------------

There are some items in FI that have high rates of missing entries, most notably family history, and efforts to optimize response to such critical data will be instituted. However, in general there was a high rate of questionnaire completion in FI compared to other cohorts. Despite some values being out of the expected range of normal (for example, BMI of 8.87), these were exceedingly rare. An advantage of the electronic data collection in FI is that it would allow real-time prompts to participants who enter unexpected values and this will be considered in the future to further minimize such entries.

A key consideration in regard to limitations of online-only data is the accuracy of self-reported PD, which we are currently not able to directly assess. Even with physician assessment, diagnostic accuracy for PD can be low early on in the course of parkinsonism, especially among older adults \[[@ref036]\]. Data on self-reported diagnostic accuracy of PD are few. In a population-based study ascertaining PD self-report by semi-structured interview (by a lay interviewer), accuracy of self-reported was only 40% compared to death certificate and neuropathological diagnosis \[[@ref037]\]. This misclassification is potentially compounded further due to errors in unsupervised self-report. The reported specialty of the diagnosing physician \[[@ref038]\] and similarities of responses in the FI cohort and comparator cohorts (prevalence of motor/non-motor symptoms, use of PD medications) provide a preliminary indication that the FI PD diagnosis may be largely accurate. However, this can only be confirmed with properly designed validation studies; a study to validate self-reported diagnosis in the FI PD cohort through telemedicine assessment by a neurologist is underway \[[@ref040]\].

As for limitations of this study, expert consensus, rather than validated approaches, was used to identify and assign assessments across cohorts that were felt to measure similar domains due to different instruments being used across studies. As harmonization of study assessments occurs in future PD research studies, a repeat of this analysis, comparing FI cohort characteristics to other cohorts that used the same assessments, will be needed. Given the heterogeneity of PD, including within-subject fluctuations in symptoms, the cross-sectional nature of this analysis is also a limitation to what conclusions can be drawn. Another limitation of this study is that it did not address the key data quality issue related to the validity of questionnaires for online-only administration. Most of the questionnaires administered have not been specifically validated for unsupervised survey administration. It is possible that with in-person administration, instructions and clarifying questions modify the responses provided. However, a high degree of agreement between remote and in-person administered responses on key instruments such as the MDS-UPDRS has been found in a previous study \[[@ref006]\].

The results of this analysis indicate that research utilizing data from an online-only self-reported PD cohort is feasible, and that a cohort assembled in this way has features that are broadly similar to cohorts recruited in person. Participants have a wide range of ages and disease durations. The patterns of FI cohort responses are similar in many respects to cohorts assessed in-person. Work is ongoing to further validate the FI cohort and platform, including, in particular, confirming self-reported diagnosis through direct assessment. Ongoing efforts also aim to increase recruitment of participants who traditionally do not have access to in-person research studies. By following a PD sample unprecedented in size and scope, the FI cohort can therefore serve to further our understanding of the frequency, severity, and progression of symptoms and quality of life in PD.

CONFLICT OF INTEREST {#sec0150}
====================

The authors have no conflict of interest to report.

Supplementary Material
======================

###### Supplementary Tables

###### 

Click here for additional data file.

The Fox Insight Study is funded by The Michael J. Fox Foundation for Parkinson's Research. We would like to thank the Parkinson's community for participating in this study to make this research possible.

Thanks to William Macintyre and Siddhi Shrivastav for their contributions.

Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database ([www.ppmi-info.org/data](www.ppmi-info.org/data)). For up-to-date information on the study, visit [www.ppmi-info.org](www.ppmi-info.org). PPMI -- a public-private partnership -- is funded by the Michael J. Fox Foundation for Parkinson's Research funding partners Abbvie, Allergan, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol-Myers Squibb, Celgene, Denali, GE Healthcare, Genentech, GlaxoSmithKline, Golub Capital, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Prevail, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily, and Voyager Therapeutics.The full list of funding partners is found at [www.ppmi-info.org/fundingpartners](www.ppmi-info.org/fundingpartners).

Data used in preparation of this manuscript were obtained from the PDBP Consortium, part of the NINDS at NIH.

The supplementary material is available in the electronic version of this article: <https://dx.doi.org/10.3233/JPD-191808>.

**Executive Steering Committee:** Caroline M. Tanner, MD PhD^1^ (PI), Ethan Brown, MD^1^, Monica Korell^1^, Catherine Kopil, PhD^2^, Luba Smolensky^2^, Vanessa Arnedo^2^, Daisy Daeschler^2^, Lindsey Riley^2^, Connie Marras, MD PhD^3^, Lana Chahine, MD^4^, Roseanne D. Dobkin, PhD^5^, Ken Marek, MD^6^, David G. Standaert, MD, PhD^7^, Marissa Dean, MD^7^

**Steering Committee:** Study Core PI / Reps (below), Ninad Amondikar^2^, Stephen Gradinscak^2^, Ira Shoulson, MD^8^, Kevin Kwok, PharmD, Will McIntyre, Helen Rowbatham^9^, Madeleine Schloetter^9^, Paul Cannon PhD^9^

**Study Cores:**

*Leadership Core:* Caroline M. Tanner, MD PhD^1^ (Study PI), Ethan Brown^1^, MD, Monica Korell, MPH^1^

*Epi Statistics Core*: Chris Baglieri^10^ (Core PI), Amanda Christini^10^, Leonardo Guercio^10^, Mark

Hollenbeck^10^ Traci Schwieger^11^, Chelsea Caspell-Garcia^11^, Janel Barnes^11 (^2017 -- 2018)

*Bioinformatics Core:* Arthur Toga, PhD^12^ (Core PI), Karen Crawford^12^, Scott Neu^12^

*Data Capture / ePRO Core*: Shawn Cimock^13^, Britt Winn^13^, Jesse Manning^13^

*Psychometrics Core*: Rochelle Tractenberg, PhD^14^, Futoshi Yumoto (2017 -- 2018)

**Study Collaborators:** Regulatory Consultant: Emily Flagg

**Affiliations:**

^1^University of California, San Francisco & San Francisco Veterans Affairs Medical Care Plan, San Francisco, CA, USA

^2^The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA ^3^Toronto Western Hospital, Toronto, Canada

^4^University of Pittsburgh, Pittsburgh, PA, USA

^5^Rutgers, The State University of New Jersey, Piscataway, NJ, USA

^6^Institute for Neurodegenerative Disorders, New Haven, CT, USA

^7^University of Alabama at Birmingham; Birmingham, AL, USA

^8^University of Rochester, Rochester, NY, USA

^9^23and Me Inc., Mountain View, CA, USA

^10^Blackfynn, Philadelphia, PA, USA

^11^University of Iowa, Iowa City, IA, USA

^12^University of Southern California, Institute for Neuroimaging and Informatics, Los Angeles, CA, USA

^13^Mondo Robot, Boulder, CO, USA

^14^Georgetown University, Washington, DC, USA

[^1]: See [appendix](#app1){ref-type="app"}.
